前列地尔联合缬沙坦对糖尿病肾病患者的临床治疗效果研究

Clinical Efficacy of Alprostadil Combined with Valsartan on Patients with Diabetic Nephropathy

目的观察前列地尔配合缬沙坦在糖尿病肾病治疗中的效果。方法将100例糖尿病肾病患者随机分成对照组和研究组,每组各50例。对照组给予缬沙坦,研究组给予缬沙坦配合前列地尔。治疗3个月后,对比两组患者血肌酐、尿蛋白定量、血浆总蛋白、血浆白蛋白等指标水平的变化。结果与治疗前相比,治疗后两组患者血肌酐、尿蛋白定量明显下降,血浆总蛋白、血浆白蛋白明显上升,差异有统计学意义(P<0.05);但研究组改善的程度更显著,与对照组相比,差异有统计学意义(P<0.05)。结论对于糖尿病肾病患者,给予缬沙坦配合前列地尔治疗有利于改善各项临床指标,改善患者临床症状,值得推广应用。

Objective To investigate the clinical effect of alprostadil combined with valsartan on patients with diabetic nephropathy. Methods 100 cases of patients with diabetic nephropathy were randomly divided into control group and study group, 50 cases per group. Patients in control group were given valsartan, and patients in study group were given valsartan combined alprostadil. After 3 months of the treatment, the serum ereatinine, urinary protein quantitation, plasma total protein, and plasma albumin levels of two groups were compared. Results After the treatment, the serum creatinine, urinary protein quantitation levels of two groups were significantly decreased, and the plasma total protein, plasma albumin levels of two groups were significantly increased, all the difference was statistical significant （P〈0.05）. The improvement degree of the study group was more significantly than that of the control group, with statistical difference （P 〈0.05）. Conclusions For patients with diabetic nephropathy, valsartan combined with alprostadil can effectively improve their clinical indicators and clinical symptoms, which is worthy of promotion and application.